BIO Form 4: EVP Barry James vests RSUs and sells 378 shares at $295.43

Rhea-AI Filing Summary

Bio-Rad Laboratories insider change: Barry James, EVP and President, LSG, reported acquisition and disposition activity on 09/05–09/06/2025. On 09/05/2025 4,110 restricted stock units (each convertible into one Class A share) vested, and 4,110 shares are shown as beneficially owned following that vesting. On 09/06/2025 an additional 1,056 restricted stock units were recorded as acquired via vesting, increasing the reported RSU-derived holdings. The Form 4 also shows a separate transaction on 09/06/2025 with code F disposing of 378 shares at $295.43 per share. Following the transactions, the filing reports 1,587.555 and 1,209.555 shares in two non-derivative lines and 4,110 and 3,168 RSU-derived shares in derivative lines as beneficially owned in the respective entries.

Positive

• 4,110 restricted stock units vested on 09/05/2025, converting to the same number of Class A shares
• Clear disclosure of RSU terms: each RSU equals one share and vests 25% per year over four years

Negative

• Disposition of 378 shares on 09/06/2025 at $295.43 per share (transaction code F)

Insights

Financial Analyst

TL;DR Insider received vested RSUs and made a small sale; impact appears routine and non-material to valuation.

The Form 4 shows standard equity compensation vesting and a contemporaneous sale. The material facts are: 4,110 RSUs vested on 09/05/2025, an additional 1,056 RSUs recorded on 09/06/2025, and a disposal of 378 shares at $295.43 on 09/06/2025. These items are consistent with scheduled equity compensation vesting and a partial sale; the filing does not disclose any unusual timing, size relative to outstanding shares, or planned 10b5-1 reliance. From a financial-model perspective, these transactions reflect compensation conversion to shares and a small monetization event but provide no new operational or financial performance information.

Corporate Governance Expert

TL;DR Disclosure is compliant with Section 16 reporting: vesting and a sale were reported and the form is signed.

The filing identifies the reporting person as Barry James, an officer (EVP, President, LSG), and includes signature dated 09/08/2025. It documents the nature of the RSUs (one RSU equals one Class A share) and the vesting schedule (25% per year over four years). The form uses transaction codes M for vesting and F for a sale; it contains the required explanatory remarks about RSU conversion and vesting cadence. There are no governance-related warnings, amendments, or indications of coordinated group filings in the document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BARRY JAMES

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, President, LSG

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/06/2025		M		1,056(1)	A	$0	1,587.555	D
Bio-Rad A Common Stock	09/06/2025		F		378	D	$295.43	1,209.555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/05/2025		A		4,110		(3)	(3)	Bio-Rad A Common Stock	4,110	$0	4,110	D
Restricted Stock Units	$0(2)	09/06/2025		M			1,056	(3)	(3)	Bio-Rad A Common Stock	1,056	$0	3,168	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ James Barry	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did BIO insider Barry James report on Form 4?

The filing reports vesting of 4,110 RSUs on 09/05/2025, vesting of 1,056 RSUs on 09/06/2025, and a sale of 378 shares at $295.43 on 09/06/2025.

How do the restricted stock units reported by Barry James convert to shares?

The Form 4 states each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock upon vesting.

What is the RSU vesting schedule disclosed in the filing?

The RSUs vest over four years at 25% per year on each yearly anniversary of the grant.

What is the reporting person's role at BIO?

The reporting person is identified as Barry James, an officer with title EVP, President, LSG.

When was the Form 4 signed by the reporting person?

The signature block shows /s/ James Barry dated 09/08/2025.